Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Stock Rated “Moderate Buy” by Sell-Side Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $39.00.

A number of research analysts recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Finally, HC Wainwright restated a “buy” rating on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd.

Artiva Biotherapeutics Trading Up 0.7%

Shares of NASDAQ:ARTV opened at $5.89 on Tuesday. Artiva Biotherapeutics has a 12-month low of $2.96 and a 12-month high of $14.53. The stock has a 50 day moving average of $9.21 and a 200 day moving average of $9.29.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). As a group, research analysts expect that Artiva Biotherapeutics will post -2.62 earnings per share for the current year.

Insider Buying and Selling

In other Artiva Biotherapeutics news, insider Subhashis Banerjee sold 8,222 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total value of $98,746.22. Following the sale, the insider owned 142,047 shares in the company, valued at $1,705,984.47. The trade was a 5.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ra Capital Management, L.P. acquired 24,944 shares of the company’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $9.93 per share, with a total value of $247,693.92. Following the acquisition, the director directly owned 17,329,570 shares in the company, valued at approximately $172,082,630.10. The trade was a 0.14% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 231,091 shares of company stock worth $2,300,259 and sold 137,048 shares worth $1,086,167. 1.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently made changes to their positions in ARTV. Squarepoint Ops LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter valued at approximately $144,000. Spark Investment Management LLC bought a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $160,000. Alyeska Investment Group L.P. increased its stake in Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after acquiring an additional 173,615 shares during the last quarter. Nantahala Capital Management LLC bought a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $2,910,000. Finally, 5AM Venture Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $22,827,049.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.